Every 10-Q that Rapid Micro Biosystems, Inc. (RPID) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RPID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPID filings page.
Rapid Micro Biosystems, Inc. reported continued operating losses for the quarter ended June 30, 2026 while modestly growing revenue. Total revenue for the quarter was $8,054 (in thousands), up from $7,262 (in thousands) a year earlier, with $5,049 (in thousands) from recurring consumables and service contracts.
Gross margin improved to $1,212 (in thousands), but operating expenses of $13,534 (in thousands) led to a loss from operations of $12,322 (in thousands) and a quarterly net loss of $12,923 (in thousands). For the first six months of 2026, net loss was $27,198 (in thousands) and operating cash outflows were $27,760 (in thousands). Cash and cash equivalents were $14,687 (in thousands) and short-term investments $5,079 (in thousands), with total assets of $58,450 (in thousands) and stockholders’ equity of $17,748 (in thousands).
Liquidity is supported by a $20,000 (in thousands) term loan under a $45,000 (in thousands) facility with Trinity Capital Inc., bearing interest of 11.0% at June 30, 2026, and by May 2026 related-party equity offerings that raised approximately $8,900 (in thousands) net. The company expects existing cash, investments and anticipated borrowing capacity to fund operations for at least 12 months, assuming revenue growth, gross margin improvement, and cost control.
Rapid Micro Biosystems, Inc. reported Q1 2026 revenue of $8.0 million, up modestly from $7.2 million a year earlier, driven by higher product revenue. Service revenue declined slightly.
The company posted a net loss of $14.3 million (loss of $0.31 per share), widening from a $11.3 million loss in Q1 2025, as operating expenses rose to $14.2 million, led by higher general and administrative and sales and marketing costs. Operating cash outflow was $15.1 million, and total stockholders’ equity fell to $20.4 million from $33.2 million at year-end 2025.
Cash, cash equivalents and short-term investments totaled about $22.9 million as of March 31, 2026, alongside a $20.0 million term loan under a facility of up to $45.0 million. Management believes existing cash, investments and expected borrowing capacity will fund operations and capital needs for at least twelve months.
Rapid Micro Biosystems (RPID) reported Q3 2025 results and added new debt capacity. Revenue was $7.8 million, essentially flat year over year ($7.6 million). Product revenue was $5.2 million and service revenue $2.6 million. The company recorded a net loss of $11.5 million, similar to the prior year’s $11.3 million, as operating expenses and cost of sales remained elevated.
For the first nine months, revenue rose to $22.3 million from $19.8 million, while net loss narrowed to $34.6 million from $37.2 million. Cash and cash equivalents were $18.9 million and short‑term investments $22.3 million as of September 30, 2025. Deferred revenue stood at $5.1 million, supporting future service activity.
On August 8, 2025, the company entered a loan and security agreement of up to $45.0 million with Trinity Capital, drawing $20.0 million initially at a minimum interest rate of 11.0% (initially 11.5%). In connection, RPID issued warrants for 179,104 Class A shares at a $3.35 exercise price; a warrant liability of $0.36 million was recorded. Operating cash outflow was $27.8 million for the nine‑month period. As of October 31, 2025, Class A shares outstanding were 39,823,026 and Class B were 4,499,529.
Rapid Micro Biosystems reported total revenue of $7.262 million for the quarter and $14.467 million for the six months ended June 30, 2025, up from $6.618 million and $12.229 million in the comparable prior periods. The company recorded a net loss of $11.858 million for the quarter and $23.121 million year-to-date, narrowing from prior-year losses. Cash and cash equivalents were $18.333 million and short-term investments were $12.922 million, with total current assets of $60.146 million.
The company disclosed a material financing arrangement: a $45.0 million loan facility with Trinity Capital as agent, of which an initial $20.0 million tranche was drawn. Management states existing cash, investments and the initial draw from the facility are expected to fund operations for at least twelve months. The report highlights ongoing operating losses, inventory reserves, concentration among certain customers, and stock-based compensation trends.